Alexandra U Scherrer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e50307. 2012
  2. pmc Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e37983. 2012
  3. doi request reprint Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 57:24-31. 2011
  4. pmc Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 203:791-7. 2011
  5. doi request reprint Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1143-52. 2011
  6. doi request reprint Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 59:105-12. 2012
  7. doi request reprint Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 208:1102-12. 2013
  8. pmc Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns
    Jorg Schupbach
    University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses, Zurich, Switzerland
    PLoS ONE 8:e71662. 2013
  9. doi request reprint Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1271-9. 2011
  10. doi request reprint Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 53:464-71. 2010

Detail Information

Publications13

  1. pmc Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e50307. 2012
    ..The accumulation of mutations after long-lasting exposure to a failing combination antiretroviral therapy (cART) is problematic and severely reduces the options for further successful treatments...
  2. pmc Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 7:e37983. 2012
    ..Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential...
  3. doi request reprint Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 57:24-31. 2011
    ..Nucleoside reverse transcriptase inhibitors (NRTIs) are often administered in salvage therapy even if genotypic resistance tests (GRTs) indicate high-level resistance, but little is known about the benefit of these additional NRTIs...
  4. pmc Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 203:791-7. 2011
    ..Following detection, individuals with Q151M tended to have lower suppression rates and higher mortality rates, relative to control subjects. Additional studies are needed to verify these findings in non-subtype B infections...
  5. doi request reprint Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1143-52. 2011
    ..The analysis of the impact of different HIV subtypes on treatment outcome is important...
  6. doi request reprint Polymorphic mutations associated with the emergence of the multinucleoside/tide resistance mutations 69 insertion and Q151M
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 59:105-12. 2012
    ..We hypothesized that polymorphic mutations exist that are associated with the emergence of the multinucleoside resistance mutations (MNR), 69 insertion and Q151M...
  7. doi request reprint Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland
    J Infect Dis 208:1102-12. 2013
    ..They may result from de novo mutagenesis or transmission. To date, the latter has not been proven...
  8. pmc Simple estimation of incident HIV infection rates in notification cohorts based on window periods of algorithms for evaluation of line-immunoassay result patterns
    Jorg Schupbach
    University of Zurich, Institute of Medical Virology, Swiss National Center for Retroviruses, Zurich, Switzerland
    PLoS ONE 8:e71662. 2013
    ..In order to use these algorithms like other TRIs, i.e., based on their windows, we now determined their window periods...
  9. doi request reprint Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection
    Philip Rieder
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Switzerland
    Clin Infect Dis 53:1271-9. 2011
    ..We analyzed HIV-1 transmission in relation to viral and host characteristics within the Zurich primary HIV-1 infection study...
  10. doi request reprint Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures
    Alexandra U Scherrer
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    J Acquir Immune Defic Syndr 53:464-71. 2010
    ..Raltegravir (RAL) achieved remarkable virologic suppression rates in randomized-clinical trials, but today efficacy data and factors for treatment failures in a routine clinical care setting are limited...
  11. pmc Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection
    Adrian Schmid
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 5:e13310. 2010
    ..In the current study, HIV-1 RNA transcription patterns in peripheral blood mononuclear cells (PBMC) were monitored during acute cART to assess the effect of early treatment on cellular viral reservoirs...
  12. pmc Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection
    Karin J Metzner
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
    PLoS ONE 6:e21734. 2011
    ..These mutations are key mutations conferring drug resistance to reverse transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations...
  13. pmc Diagnostic performance of line-immunoassay based algorithms for incident HIV-1 infection
    Jorg Schupbach
    Swiss National Center for Retroviruses, Institute of Medical Virology, University of Zurich, Switzerland
    BMC Infect Dis 12:88. 2012
    ....